Study Builds on Extensive Published Literature
Highlighting the Benefits of the CyberKnife System in the Treatment
of a Wide Range of Neurological Indications
MADISON, Wis.,
Dec. 18,
2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:
ARAY) announced today an international retrospective
multicenter analysis found that radiosurgery (SRS) and fractionated
stereotactic radiotherapy (FSRT), delivered with the
CyberKnife® System, can provide an effective and
time-saving treatment option for brainstem metastases (BSM). The
nine institution study results, published in the International
Journal of Cancer, "underscore the long-term benefits in local
control and the robust safety profile despite the delicate location
of the treated metastases1."
"The brainstem is an integral part of the central nervous
system, and metastatic spread to this part of the brain is a
potentially life-threatening situation. Since surgical resection is
rarely an option, stereotactic radiosurgery and fractionated
stereotactic radiotherapy are both effective and safe treatment
options when thoroughly planned and executed. The available
literature, along with our multicenter study, clearly underscores
the central role of radiosurgery for affected patients," said
Felix Ehret, M.D., Department of
Radiation Oncology, Charité - Universitätsmedizin Berlin and European Radiosurgery Center
Munich, Munich, Germany.
SRS and FSRT – also referred to as fractionated radiosurgery –
are advanced forms of radiation therapy. SRS delivers a high dose
of radiation in one session, while FSRT divides the total treatment
dose into multiple, smaller doses given over several days. Both
techniques provide medical care teams with the ability to deliver
extremely precise, very targeted doses of radiotherapy, typically
to small, specific areas within the body, usually in the brain. In
the reported analysis, 136 patients who received treatment in one
to five sessions were analyzed; 69.4 percent received radiotherapy
in just one treatment dose1.
"The brain's tissues and structures are incredibly delicate and
are essential to everything from basic functions to the very
essence of who we are as individuals. That's why we developed the
CyberKnife System to deliver radiation with the utmost accuracy and
precision, and why we remain committed to innovating for better
clinical outcomes for people with brain tumors, lesions, and benign
neurological conditions," said Seth Blacksburg, M.D., MBA, Chief
Medical Officer at Accuray.
CyberKnife System Expands Treatment Options for People
with Brain Tumors and Neurological Conditions
The
CyberKnife System can be used to treat brain tumors and
neurological conditions with sub-millimeter accuracy and precision
in just one to five sessions over one to two weeks. With the
CyberKnife System, patients aren't required to have a metal frame
attached to their head to undergo treatment, enabling a wide range
of people, including those with recurrent tumors and young patients
who can't be treated with a fixed head frame, to benefit from a
shorter overall course of care that may positively impact their
quality of life. The CyberKnife System can also be used at various
stages in the treatment journey – from first line to adjuvant
therapy and palliation – reinforcing its benefits in daily
practice.
About the Study
The objective of this analysis was to provide further evidence for
the use of radiosurgery in the treatment of patients with BSM. The
retrospective evaluation compared the safety and efficacy results
achieved by nine institutions delivering radiotherapy in single
(SRS) and up to five sessions (FSRT) with the
CyberKnife® System to available published literature on
these techniques. The multicenter study assessed 136 patients with
144 BSM who received treatment from 2005 to 2022. One hundred BSM
were treated with SRS, and the remaining 44 received FSRT. The
results showed one-year, two-year, and three-year local BSM control
rates were 82.9 percent, 71.4 percent, and 61.2 percent. This study
helps to underscore the long-term benefits in local control despite
the delicate position of the treated metastases. SRS and FSRT
treatments were well tolerated and the incidence of
treatment-related side effects was low.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Madison, Wisconsin, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, X, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to expectations related to the
use of the Company's products in the treatment of neurological
indications, clinical applications, clinical results and outcomes,
patient experiences and patient outcomes. These forward-looking
statements involve risks and uncertainties. If any of these risks
or uncertainties materialize, or if any of the company's
assumptions prove incorrect, actual results could differ materially
from the results expressed or implied by these forward-looking
statements. These risks and uncertainties include, but are not
limited to, the company's ability to achieve widespread market
acceptance of its products, including new product innovations and
releases; the company's ability to develop new products or improve
existing products to meet customers' needs; the company's ability
to anticipate or keep pace with changes in the marketplace and the
direction of technological innovation and customer demands and such
other risks identified under the heading "Risk Factors" in the
company's quarterly report on Form 10-Q, filed with the Securities
and Exchange Commission (the "SEC") on November 6, 2024, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
1 Ehret F, Rueß D, Blanck O, et al. Stereotactic
radiosurgery and radiotherapy for brainstem
metastases: An international multicenter analysis. Int J Cancer.
2024;155(5):916‐924. doi:10.1002/ijc.34980
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-data-indicates-the-cyberknife-system-can-provide-a-safe-and-effective-treatment-option-to-control-brainstem-metastases-an-extremely-challenging-location-to-treat-302334829.html
SOURCE Accuray Incorporated
